Summary:
This study investigates MK-2214's effectiveness in slowing brain changes in early Alzheimer's Disease (AD). AD is a form of dementia affecting memory and decision-making abilities. The study is a Phase 2, randomized, placebo-controlled trial. Participants will be randomly assigned to receive either MK-2214 or a placebo and will undergo tau PET imaging to assess tau protein spread. The primary outcomes are changes in tau PET SUVr and the incidence of adverse events over approximately 23 to 26 months.
Qualified Participants Must:
• Age 50-85
•
Mild cognitive impairment or mild dementia due to Alzheimer's Disease
•
Designated study partner available
•
Stable dosing regimen of approved AD therapy for 3 months prior
Qualified Participants May Receive:
Compensation for time and travel